These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Synthesis and beta-adrenergic antagonist activity of heterocyclic propanolamines.
    Author: Vo D, Wolowyk MW, Knaus EE.
    Journal: Drug Des Discov; 1993 Jun; 10(2):89-99. PubMed ID: 8104518.
    Abstract:
    The synthesis and beta-adrenergic antagonist activities of a group of 1-(heteroaryloxy)- and 1-(heteroaryl)-3-alkylamino-2-propanols is described. beta 1-Adrenolytic (atria) structure-activity correlations indicated that replacement of the 1-naphthyl moiety of propranolol by a 4-quinolyl- (10), 2-quinolyl- (24), or 2-pyrimidyl- (26) heterocyclic moiety resulted in a 10-16 fold reduction in activity. The 1-(4-quinolyloxy)- (10) and 1-(2-quinolyloxy)- (24-25) heteroaryl moieties provided more potent activity than the structurally related 1-[2-(2H-isoquinolin-1-one)]- (31-32) or 1-[3-(3H-quinazolin-4-one)]- (35-36) moieties. All compounds tested exhibited weak beta 2-adrenolytic activity on trachea. Although the most potent beta 1-antagonist, 1-(2-pyrimidyloxy)-3-isopropylamino-2-propanol (26), was 13-fold less potent than metoprolol, it exhibited a beta 1/beta 2 selectivity ratio superior to the cardioselective metoprolol.
    [Abstract] [Full Text] [Related] [New Search]